Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Diffusion Basis Spectrum Imaging of the Prostate

NCT: NCT04420702 · RECRUITING

NCT IDNCT04420702
StatusRECRUITING
Start Date2020-02-27
Completion2027-05-31
SponsorWashington University School of Medicine (OTHER)
First posted
Last updated

Brief Summary

Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

Frequently Asked Questions

What is Diffusion Basis Spectrum Imaging of the Prostate?

Diffusion Basis Spectrum Imaging of the Prostate is a clinical trial registered under NCT04420702. Current status: RECRUITING.

What is the status of NCT04420702?

The current status of NCT04420702 (Diffusion Basis Spectrum Imaging of the Prostate) is: RECRUITING.

When did Diffusion Basis Spectrum Imaging of the Prostate start?

Diffusion Basis Spectrum Imaging of the Prostate started on 2020-02-27.

Related Devices

PMA P190022Multi-analyte test system with algorithmic analysis for detection of prostate cancerOpko Health, Inc. PMA P200048Multi-analyte test system with algorithmic analysis for detection of prostate cancerCleveland Diagnostics, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑